BeOne Medicines AG (ONC)
 NASDAQ: ONC · Real-Time Price · USD
 311.86
 +1.38 (0.44%)
  Nov 3, 2025, 4:00 PM EST - Market closed
BeOne Medicines AG Employees
BeOne Medicines AG had 11,000 employees as of December 31, 2024. The number of employees increased by 400 or 3.77% compared to the previous year.
Employees 
 11,000
Change (1Y) 
 400
Growth (1Y) 
 3.77%
Revenue / Employee 
 $414,727
Profits / Employee 
 -$16,149
Market Cap 
34.33B
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 11,000 | 400 | 3.77% | 
| Dec 31, 2023 | 10,600 | 1,600 | 17.78% | 
| Dec 31, 2022 | 9,000 | 1,000 | 12.50% | 
| Dec 31, 2021 | 8,000 | 2,700 | 50.94% | 
| Dec 31, 2020 | 5,300 | 1,800 | 51.43% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
ONC News
- 6 days ago - BeOne Medicines to Present at Upcoming Investor Conferences - Business Wire
 - 12 days ago - BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6 - Business Wire
 - 14 days ago - BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 - Business Wire
 - 20 days ago - BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline - Seeking Alpha
 - 21 days ago - BeOne Medicines' Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA - Business Wire
 - 2 months ago - BeOne Medicines AG (ONC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
 - 2 months ago - BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients - Benzinga
 - 2 months ago - BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL) - Business Wire